Search

Displaying results 5291 - 5300 of 10000 in total
  1. Drug

    Cobalt

    go.drugbank.com/drugs/DB14574
    ApprovedWithdrawn

    Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis. … A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments.

  2. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  3. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … [A175909] It has been investigated as a lung cancer vaccine.

  4. Drug

    Hydracarbazine

    go.drugbank.com/drugs/DB09243
    Experimental

    Hydracarbazine is a pyridazine that has found use as an antihypertensive agent [A19790] It was once marketed in France under the tradename Normatensyl.

  5. Drug

    Magnesium glycinate

    go.drugbank.com/drugs/DB11189
    ApprovedInvestigational

    Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.

  6. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden.

  7. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

  8. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  9. Drug

    PEV3A

    go.drugbank.com/drugs/DB05144
    Investigational

    PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. … The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue _in vitro_.

  10. Drug

    Sulfabenzamide

    go.drugbank.com/drugs/DB09355
    ApprovedWithdrawn

    Sulfabenzamide is an antimicrobial agent often used in conjunction with sulfathiazole and sulfacetamide as a topical intravaginal antibacterial preparation.

    Synonyms: N-Benzoylsulfanilamide, N-Sulfanilylbenzamide